Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idenix Pharmaceuticals, a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, has reported revenues of $3.79m for the third quarter ended 30 September 2010, compared to $3.12m for the same period in 2009.
Subscribe to our email newsletter
Idenix Pharma has posted a net loss of $12.93m for the third quarter 2010, or $0.18 per diluted share, compared to $11.67m, or $0.18 per diluted share, for the comparable period in 2009.
Loss from operations was $12.86m, compared to $12m for the comparable period in 2009.
For the nine months ended 30 September 2010, Idenix Pharma has posted a revenue of $7.79m, compared to $9.57m for the year ago period.
For the nine months ended 30 September 2010, net loss was $45.4m, or $0.65 per diluted share, compared to net loss of $40.91m, or $0.69 per diluted share, for the year ago period.
Loss from operations was $46.11m, compared to $41.62m for the year ago period.